Episode 109: AB126, Exosomes, and Cerebroprotection for Stroke
Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Stephen From. [LISTEN TIME: 22 minutes]
Episode 109 of the NeurologyLive®
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
Episode 109, "AB126, Exosomes, and Cerebroprotection for Stroke" features a conversation with Stephen From, chief executive officer of Aruna Bio, who sat down to discuss the company's investigational exosome candidate AB126 and its upcoming phase 1b/2a trial in patients with ischemic stroke. He discussed the mechanism of action of the therapy, the advantages of its anti-inflammatory and neuroprotective properties, and how it will be used with other stroke treatments. Furthermore, he gave insight on the complexities with conducting stroke trials and improving neurodegeneration in poststroke patients.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
European Commission Approves Omaveloxolone as First Therapy for Friedreich Ataxia AVP-786 Falls Short in Phase 3 Study of Alzheimer Disease Agitation FDA Grants Priority Review to Efficacy Supplement for Sarepta Therapeutics’ SRP-9001 Indication Expansion
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at
EPISODE BREAKDOWN
- 1:00 – Overviewing phase 1b/2a trial
- 7:05 – Mechanism of action of AB126
- 11:15 – Neurology News Minute
- 13:45 – Role of AB126 in stroke treatment landscape
- 17:50 – Challenges with repairing neurodegeneration in stroke
Hoping to listen on your favorite podcast app? See below:
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Pathophysiology of Myasthenia Gravis
September 18th 2025